Kinase inhibitors and ovarian cancer

Periklis Katopodis, Dimple Chudasama, Gurleen Wander, Louise Sales, Juhi Kumar, Manreen Pandhal, Vladimir Anikin, Jayanta Chatterjee, Marcia Hall, Emmanouil Karteris*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)


Ovarian cancer is fifth in the rankings of cancer deaths among women, and accounts for more deaths than any other gynecological malignancy. Despite some improvement in overall-(OS) and progression-free survival (PFS) following surgery and first-line chemotherapy, there is a need for development of novel and more effective therapeutic strategies. In this mini review, we provide a summary of the current landscape of the clinical use of tyrosine kinase inhibitors (TKIs) and mechanistic target of rapamycin (mTOR) inhibitors in ovarian cancer. Emerging data from phase I and II trials reveals that a combinatorial treatment that includes TKIs and chemotherapy agents seems promising in terms of PFS despite some adverse effects recorded; whereas the use of mTOR inhibitors seems less effective. There is a need for further research into the inhibition of multiple signaling pathways in ovarian cancer and progression to phase III trials for drugs that seem most promising.

Original languageEnglish
Article number1357
Issue number9
Publication statusPublished - Sep 2019
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.


  • Kinase inhibitors
  • MTOR
  • Ovarian cancer
  • Rapalogs
  • TKI


Dive into the research topics of 'Kinase inhibitors and ovarian cancer'. Together they form a unique fingerprint.

Cite this